|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.780 HKD | +1.70% |
|
+5.74% | -22.49% |
| 06:53am | Sino Biopharmaceutical Plans HK$2 Billion Stock Buyback | MT |
| 30/05 | Sino Biopharmaceutical Limited Announces Approval For Marketing of Naldemedine For Opioid-Induced Constipation In Adults | CI |
Executive Committee: Sino Biopharmaceutical Limited
| Manager | Positions heldSince | ||
|---|---|---|---|
![S Y Tse](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>) S Y Tse 30 year |
| ||
Hsin Tse 56 year |
| ||
Chun Ling Li 55 year |
| ||
Kuen Lai |
| ||
Xiao yan Kang |
|
Composition of the Board of Directors: Sino Biopharmaceutical Limited
| Director | CommitteesSince | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Theresa Y. Y. Tse 33 year |
| ||||||||||||
Zheng Fei Lu 63 year |
| ||||||||||||
Lu Fu Zhang 69 year |
| ||||||||||||
Kwok Tung Li 71 year |
| ||||||||||||
Hong Lu 56 year |
| ||||||||||||
Cheung Ling Cheng 62 year |
| ||||||||||||
Ping Tse 74 year |
| ||||||||||||
S Y Tse 30 year |
| ||||||||||||
Da Kui Li 82 year |
| ||||||||||||
Hsin Tse 56 year |
| ||||||||||||
Zhou Shan Tian 62 year |
|
Latest Appointments: Sino Biopharmaceutical Limited
Former Officers and Directors: Sino Biopharmaceutical Limited
| Insider | Positions held SinceUntil | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
| |||||||||
|
|
Age distribution of managers
Parity Men Women
| Male | 11 |
|---|---|
| Female | 5 |
Of which Executive Committee
| Male | 3 |
|---|---|
| Female | 2 |
Of which Directors
| Male | 8 |
|---|---|
| Female | 3 |
Revisions
ESG MSCI
Departures of Key Persons
Chief Executive Officer
19/08/2020 28/07/2022
Chief Executive Officer
25/02/2010 31/07/2016
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition